🧬 The shingles vaccine is linked to a 24% lower risk of developing dementia
Recent research has shown that older adults who received the shingles vaccine known as Shingrix when they entered specialized health care centers had a 24% lower risk of being diagnosed with dementia within four years compared with those who did not receive the vaccine.
This finding adds valuable insight to the medical field, as it suggests that the vaccine not only protects against shingles but may also have potential neuroprotective benefits.
🩺 Why studying the new Shingrix vaccine in older adults matters
The study was conducted with the participation of more than 500,000 older adults over the age of 66, who entered qualified short- and long-term care facilities. Medicare data and electronic medical records were used to analyze the health status of these individuals between 2017 and 2022.
A comparison was made between those who received at least one dose of the recombinant shingles vaccine (Recombinant Zoster Vaccine – RZV), commercially known as Shingrix, and those who did not receive it, as Shingrix is the only vaccine currently available for this disease since its introduction in 2017.
The study stood out because it focused on the newest vaccine, which had not been available in earlier studies that used older vaccines. The group in question included older adults who had not been previously immunized, and their entry into the care center appeared to mark a clear starting point for providing medical care.
🧠 The vaccine’s effects on dementia risk
- The rate of dementia development over four years was 18.8% among those vaccinated with the Shingrix vaccine.
- Among the unvaccinated, the rate reached 24.6%.
- This difference reflects a reduction of about 6% percentage points, or the equivalent of a 24% lower risk of developing dementia when receiving the vaccine.
- Researchers estimate that this helps prevent one case out of every 17 dementia cases in this age group.
These findings place Shingrix in a position that is not limited to preventing the herpes zoster virus (Herpes Zoster) but extends to the field of potential neuroprotection.
🧪 Study limitations and scientific interpretations
Despite the promising results, there are important limitations in interpreting them:
- The study did not prove a direct cause-and-effect relationship between Shingrix and a lower risk of dementia.
- Individuals who received the vaccine tended to be somewhat younger and healthier than the unvaccinated group, which may affect dementia rates.
- The analysis was adjusted to account for these differences, but they did not fully explain the observed relationship.
- Scientific confirmation of the vaccine’s effect in reducing dementia risk still requires additional clinical trials focused on this aspect.
The results reflect a growing pattern in research that uncovers unexpected benefits of vaccines in areas that go beyond protection from infectious diseases to improving brain health.
🌱 Shingles vaccines and their potential role in neuroprotection
Researchers are studying the many positive findings linking shingles vaccination to a lower risk of neurological problems such as dementia, opening the door to hypotheses that vaccines may enhance neuroimmune protection.
Recombinant vaccines such as Shingrix play an important role in activating the immune system against the Varicella-Zoster virus responsible for shingles, which can remain dormant in the body for long periods.
Its link to brain health may be attributed to the fact that preventing infection with this virus may stop chronic neurological inflammation or certain immune events that negatively affect brain cells.
🧠 The relationship between physical and brain health
Researcher Callie Hayes, who supervised the study, explained that cognitive health is closely linked to our physical health. From this perspective, protecting the body from physiological diseases may result in multiple cognitive benefits.
This concept reflects the fact that the brain is not an independent entity, but part of an interconnected system that depends on overall physical health to maintain its vital functions.
🩺 Conclusion and the outlook for future research
The results of this study are an important step in identifying additional benefits that the Shingrix vaccine may provide beyond its traditional protection against shingles.
However, the researchers remain cautious about drawing a causal relationship without controlled clinical trials. They recommend further studies to determine how strengthening immunization can help protect the brain and prevent dementia.
At present, the researchers confirm that vaccination with Shingrix offers a widely available opportunity to improve the overall health of older adults, including neurological health alongside physical protection.
The study was funded by GlaxoSmithKline, the vaccine manufacturer, and it was later confirmed that this entity did not influence the study design, data analysis, or publication of the results.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
